Directors of hVIVO plc
Jaime Ellertson, Non-Executive Chairman
Jaime Ellertson was appointed non-executive Chairman of Retroscreen Virology Group PLC in June 2014. (now hVIVO PLC)
Jaime Ellertson has a strong track record of leading fast growing, data and service driven companies through phases of rapid expansion, both in the private and public arena. Jaime is currently Chairman and Chief Executive Officer of Everbridge Inc., a provider of multi-dimensional critical communications solutions to leading Health Care, Corporate and Government organisations globally.
He lives in Massachusetts and is a citizen of the United States of America. Jaime previously served as the Chief Executive Officer, President and Director of Gomez Inc., a company specialising in monitoring and managing Web site data and Web application performance. During his tenure he led Gomez Inc. through an IPO registration that resulted in the successful sale of the company for $295M to Compuware Corporation (NASDAQ: CPWR). He served as Chief Executive Officer, President and Director of S1 Corporation Inc. (NASDAQ: SONE), a software provider to the financial services marketplace. Jaime also orchestrated the highly successful turnaround of Interleaf, Inc. (NASDAQ: LEAF), a provider of software tools for e-content management, culminating in its acquisition for $852M by BroadVision Inc in 2000.
Earlier in his career, Jaime founded several high growth software companies including Openware Technologies Inc., Document Automation Corporation and Purview Technologies Inc.. He has also served on the boards of a number of public and private US and UK based companies.
Kym Lynn Denny, Chief Executive Officer
Kym Denny has been CEO of hVIVO (formerly Retroscreen Virology), a specialty respiratory biopharma company, since 2010. Kym led the Company’s highly successful IPO on AIM in 2012, and has since led several successful fund raising drives totaling almost £100M.
Kym strengthened the financial performance of hVIVO from a turnover of £1m in the 6 month period ending 31 December 2010, to £14.39m (2012), £27.5m (2013) and £18.5m (2014), and has since ensured that the company’s performance is maintained through solid growth and investment in R&D. In addition, Kym has been leading hVIVO to implement efficient business practices resulting in profit margins increasing from 14.4% (2011) to 29.4% (2014).
Kym has extensive drug development leadership experience in therapeutic areas including Infectious Disease, Respiratory, CNS, oncology, women’s health and orphan indications. She was VP of Clinical Research at SRA International, MD at Harrison Clinical Research, Board member responsible for Clinical Operations at Profiad, and Founder and President at Insite Clinical Trials.
In 2016, Kym was the Ernst & Young (EY) Entrepreneur of the Year UK category winner for Healthcare, won the Gold Award in the “Female Executive of the Year in Europe, the Middle East and Africa” category at the at the Women in Business Stevie Awards, and was appointed to the Mayor of London’s Business Advisory Board.
Graham Edward Yeatman, Chief Financial & Business Officer
Graham joined hVIVO Services Limited (formerly Retroscreen Virology Limited) as Finance Director in May 2011 and became Finance Director of hVIVO plc (formerly Retroscreen Virology Group plc) in April 2012. Graham was promoted to Chief Financial and Business Officer in January 2015.
Graham has significant experience of building businesses for rapid growth and profitability. He is a Chartered Accountant and trained and worked with PricewaterhouseCoopers for thirteen years across its audit, tax, consultancy, business process reengineering and outsourcing divisions. In 2001 he joined buyingTeam Limited (subsequently renamed Proxima) as Finance & Operations Director and was influential in growing the business to become one of the UK’s leading purchasing services providers. In 2006 he joined Neuropharm Group plc as Chief Financial Officer. Graham has a First in Economics and Maths from Bristol University.
Dr Trevor Nicholls, Non-Executive Director
Dr Trevor Nicholls became a non-executive director of the Company on 21 May 2014.
Trevor is a company director having over 30 years of building international businesses in the life science industry, with a strong focus on genomics and proteomics. In particular, he was previously Chairman of Oxford Nanopore Technologies Limited, is currently Chairman of Avacta Group plc and was the Chairman of Activiomics Limited prior to its acquisition by Retroscreen. Trevor is also Chief Executive Officer of CABI, a not-for-profit inter-governmental organisation owned by 46 member countries worldwide. Prior to his current role with CABI, he was Chief Commercial Officer for Affymetrix Inc with accountability for global operations, delivering $330 million revenue with 600 staff across 8 locations worldwide.
His technology knowledge and leadership will be invaluable as Retroscreen expands its bio-analytical activities.
Dr. Trevor Phillips, Non-Executive Director
Dr Trevor Phillips became a non-executive director of the Company on 20 June 2017.
Trevor has over thirty years’ of experience within the pharmaceutical industry, including extensive international drug development and corporate development responsibilities. He was previously Chief Operations Officer and President of US Operations, as well as a member of the Board, at Vectura Group plc, a FTSE 250 company listed on the London Stock Exchange focused on respiratory diseases. Subsequent to joining Vectura in 2010, Trevor played an integral leadership role in the company’s successful development, including the acquisition of Activaero GmbH in 2014 and the merger with Skyepharma plc in 2016.
Prior to joining Vectura, Trevor held the roles of Chief Executive Officer and Chief Operating Officer at Critical Therapeutics, Inc. (now Chiesi USA, Inc.), a US listed specialty pharmaceutical company. He has also held senior management positions at Sepracor, Inc. (now Sunovion Pharmaceuticals, Inc.), Accenture plc and GlaxoWellcome plc (now GlaxoSmithKline plc). Trevor trained as a microbiologist at University of Reading, obtaining a PhD in microbial biochemistry from the University of Wales in 1986. He was awarded an MBA from Henley Management College in 1997.
Dr Mark Warne, Non-Executive Director
Mark Warne became a Non‑Executive Director of hVIVO in April 2016 and will act as Chairman of the Remuneration Committee.
He is currently Head of IP Group’s Healthcare division, which at the end of December 2015, had shareholdings in 31 companies valued at over £275 million. Mark also represents IP Group on the boards of a number of its portfolio companies, both quoted and private; notably Genomics plc, Cronin Group plc and Crysalin Limited.
Mark has been at IP Group since 2008 and has extensive experience in building world‑changing healthcare businesses as well as in managing transactions including portfolio company IPOs, financings and M&A. He joined IP Group from pre‑clinical drug discovery CRO, Exelgen, where he was Managing Director. Mark spent eight years at Exelgen (formerly known as Tripos Discovery Research) where he also held positions in licensing and strategic affairs, project management and research. He has a PhD in Computational Chemistry, an MSc in Colloid Science and a BSc in Chemistry, all from the University of Bristol. Mark is a Chartered Chemist and member of the Royal Society of Chemistry.
James F. Winschel, Non-Executive Director
James F. Winschel became a non-executive director of the Company on 1 October 2014 and is Chairman of the Audit Committee.
Jim retired in June 2014 as Executive Vice President at PAREXEL International Corporation (“PAREXEL”), a US publicly-traded healthcare services company (NASDAQ: PRXL) with $1.9 billion in annual service revenue. He previously served as Senior Vice President and Chief Financial Officer of PAREXEL from 2000 to 2013, with responsibility for directing all financial activities, during a period when PAREXEL’s revenue grew by $1.5 billion, backlog increased by $4.5 billion and market capitalisation increased from $225 million to $2.7 billion.
Jim is currently a Director of Cambrex Corporation, a US company offering products, services and technologies to accelerate the development and commercialisation of small molecule therapeutics. Earlier in his career, Jim spent five years at BTM Capital Corporation, a Bank of Tokyo-Mitsubishi Ltd. subsidiary, initially as Executive Vice President and Chief Financial Officer for three years from 1995 before being promoted to President, U.B. Vehicle Leasing, Inc. through 2000. Prior to these roles, he was the Vice President – Finance, Physician Services Division at Caremark International, Inc. for two years from 1993 and spent the previous four years at Whirlpool Financial Corporation (WFC), both as the Vice President & Managing Director, Commercial Financing Division and prior to that as the Vice President and Chief Financial Officer. Jim worked for five years in various roles at General Electric Capital Corporation, in the Transportation and Industrial Financing Division and prior to that at General Electric Company for eleven years.
Jim holds an MBA in Accounting and a BSc in Finance from Syracuse University in the USA.